Refractory Primary Immune Thrombocytopenia in Pregnancy. A Case of Study
Abstract
Primary immune thrombocytopenia (PIT) is a common autoimmune disorder that varies with patients of all ages, genders, and races. The diagnosis excludes all those thrombocytopenias due to other autoimmune diseases, infections, or drugs so that no alteration is evident in the remaining cell lines. More than 80 % of autoimmune thrombocytopenias respond favorably to first-line treatments and, the remaining 20 %, up to 60 % will resolve with second-line treatments. Only 3 % to 8 % will not respond to conventional management, thus setting up refractory immune thrombocytopenia, therefore becoming a therapeutic challenge. The incidence of refractory immune thrombocytopenia is unknown during pregnancy and is limited to the reports of a few cases in the literature. We present the case of a pregnant woman with a history of pit that became refractory during pregnancy with persistently low platelet counts, bleeding symptoms and therapeutic limitations due to her preg- nant condition.
Downloads
References
Kistangari G, McCrae K. Immune Thrombocytopenia. Hematol Oncol Clin N Am. 2013;27,495-520. DOI: https://doi.org/10.1016/j.hoc.2013.03.001
Sanz M, García V, Fernández A, Lópe M, Grande C, Jarque I, et al. Diagnóstico, tratamiento y seguimiento de la trombocitopenia inmune primaria. Med Clín. 2012;138:6,1-17. DOI: https://doi.org/10.1016/j.medcli.2011.11.011
Cuker A, Neunert C. How I treat refractory immune thrombocytopenia. Blood. 2016;12,1547-1554. DOI: https://doi.org/10.1182/blood-2016-03-603365
Perera M, Garrido T. Advances in the Pathophysiology of Primary Immune Thrombocytopenia. Hematology. 2017; 22:1, 41-53. DOI: https://doi.org/10.1080/10245332.2016.1219497
Care A, Pavord S, Knight K, Alfirevic Z. Severe Pri- mary Autoimmune Thrombocytopenia in Pregnancy: A National Cohort Study. BJOG. 2018;125:604-612. DOI: https://doi.org/10.1111/1471-0528.14697
Loustau V, Debouverie O, Canoui-Poitrine F, Baili L, Khellaf M, Touboul C, et al. Effect of Pregnancy on the Course of Immune Thrombocytopenia: A Retrospective Study of 118 Pregnancies in 82 Women. Brit J Haemat. 2014;166,929-935. DOI: https://doi.org/10.1111/bjh.12976
Gilmore K, McLintock C. Maternal and Fetal Outcomes of Primary Immune Thrombocytopenia During Pregnancy: A Retrospective Study. Obst Med. 2018;11:1,12- 16. DOI: https://doi.org/10.1177/1753495X17727408
Decroocq J, Marcellin L, Le Ray C, Willems L. Rescue Therapy With Romiplostim for Refractory Primary Immune Thrombocytopenia During Pregnancy. Am Coll Obst Gynec. 2014;124:2,481-483. DOI: https://doi.org/10.1097/AOG.0000000000000371
Neunert C. Management of Newly Diagnosed Im- mune Thrombocytopenia: Can We Change Outco- mes? Bl Adv Hemat. 2017;1,400-405. DOI: https://doi.org/10.1182/asheducation-2017.1.400
Rodríguez R, Rubio L, Palomo A, Langenhorst L. Use of Romiplostim During Pregnancy as a Rescue Therapy in Primary Immune Thrombocytopenia: Literature Review And Case Description. Plat. 2019;1-4.
